ReviewiLIVER2024
Prognostic role of selection criteria for liver transplantation in patients with hepatocellular carcinoma: Review and bibliometric.
Review in iLIVER, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Multiphase MRI radiomics model for predicting microvascular invasion in HCC: Development and clinical validation.iLIVER · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is one of the most common cancers in the world and is one of the leading indications for liver transplantation, liver transplantation is the gold standard treatment for end stage liver disease. Diagnosis is based up on radiological characteristics and rarely biopsy results. However treatment must be individualized to each patient to improve recurrences and outcomes. In this article, we focus on the different selection criteria for liver transplantation. This study aimed to investigate the distribution laws and research frontiers of international literature, so as to present holistic bibliometric evaluation of the studies on 5-year survival and disease-free recurrence in 5 years, according to hepatocarcinoma criteria for liver transplantation. The paper aims to review and analyze 5-year survival and disease-free recurrence based on hepatocarcinoma criteria for liver transplantation. It systematically examines and summarizes distribution characteristics and research frontiers through bibliometric analysis. A bibliographic search was implemented in PubMed/Medline, Clinical Key, Science Direct and Index Medicus with MESH terms, from the year 1996-2022. Patients selected for transplantation using the Metroticket 2.0 (MT2) criteria had the highest overall survival along with patients selected for transplantation using the Milan Criteria had the best 5-year disease-free recurrence. The Metroticket 2.0 criteria (MT2) and Milan Criteria (MC) have shown the most favorable post-transplant outcomes for patients with hepatocellular carcinoma (HCC). However, MC demonstrated the best 5-year disease-free recurrence rate, underscoring the significance of taking into account tumor morphology and biology when determining the eligibility of HCC patients for liver transplantation. The distribution characteristics and research frontiers by bibliometrics concerning prognostic role of selection criteria for liver transplantation in patients with hepatocellular carcinoma the collaborations are sufficient to reach a consensus that the Milan criteria are the best criteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.